IL269123A - Methods of treating cancer - Google Patents

Methods of treating cancer

Info

Publication number
IL269123A
IL269123A IL26912319A IL26912319A IL269123A IL 269123 A IL269123 A IL 269123A IL 26912319 A IL26912319 A IL 26912319A IL 26912319 A IL26912319 A IL 26912319A IL 269123 A IL269123 A IL 269123A
Authority
IL
Israel
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
IL26912319A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of IL269123A publication Critical patent/IL269123A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL26912319A 2017-03-07 2019-09-04 Methods of treating cancer IL269123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468259P 2017-03-07 2017-03-07
PCT/US2017/052663 WO2018164715A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Publications (1)

Publication Number Publication Date
IL269123A true IL269123A (en) 2019-11-28

Family

ID=63447943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26912319A IL269123A (en) 2017-03-07 2019-09-04 Methods of treating cancer

Country Status (9)

Country Link
EP (1) EP3592357A4 (https=)
JP (1) JP7042836B2 (https=)
KR (1) KR20190122251A (https=)
CN (1) CN110430882A (https=)
AU (1) AU2017402623A1 (https=)
CA (1) CA3055308A1 (https=)
IL (1) IL269123A (https=)
TW (1) TW201832768A (https=)
WO (1) WO2018164715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022011037A2 (en) * 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
WO2023043375A2 (en) * 2021-09-16 2023-03-23 Agency For Science, Technology And Research Modulation of tjp1 expression to treat liver diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
WO2018164715A1 (en) 2018-09-13
KR20190122251A (ko) 2019-10-29
TW201832768A (zh) 2018-09-16
EP3592357A1 (en) 2020-01-15
CN110430882A (zh) 2019-11-08
JP2020510009A (ja) 2020-04-02
JP7042836B2 (ja) 2022-03-28
AU2017402623A1 (en) 2019-09-26
EP3592357A4 (en) 2021-01-13
CA3055308A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
IL263925A (en) Methods of treating ovarian cancer
IL262342A (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
ZA201808258B (en) Methods of treating pancreatic cancer
PT3490560T (pt) Niraparib para utilização num método de tratamento de cancro da próstata
ZA201908539B (en) Method of treatment of cancer
SG11202010793UA (en) Methods of treating cancer
IL263835A (en) Exosome-guided treatment of cancer
IL281600B2 (en) Cancer treatment methods
EP3487999A4 (en) METHODS OF TREATING CANCER
GB201717945D0 (en) Method for treatment of cancer
SG11202005163PA (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
IL274748A (en) Improved cancer treatment
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
SG11202000839TA (en) Methods of treating cancer by inhibiting setd2
HK40032563A (en) Methods of treating cancer
GB201702139D0 (en) Methods of cancer treatment
HK40016485A (en) Methods of treating cancer
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer